Physician profile
Monica Patel
NPI 1295070910
$9,593.94
in general payments reported to CMS, 2019-2025
14 companies · $7,236 in 2025
The $7,236 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $778 · 2024: $1,385 · 2025: $7,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,030 · Food and Beverage: $3,293 · Education: $76.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,030.00 |
| Food and Beverage | $3,293.33 |
| Education | $76.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $6,664.04 | 2022-2025 | Cequa |
| Bausch & Lomb Americas INC. | $1,033.37 | 2023-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Harrow Eye, LLC | $345.82 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $333.96 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $226.83 | 2023-2025 | Rocklatan |
| Mallinckrodt Hospital Products INC. | $225.88 | 2022-2024 | Acthar |
| Sight Sciences, INC. | $207.77 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Oyster Point Pharma, INC. | $161.75 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $109.88 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Thea Pharma INC. | $94.07 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $82.32 | 2024 | Oxervate |
| Biotissue Holdings INC. | $49.85 | 2025 | |
| Amgen INC. | $38.86 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $19.54 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.